{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06101342",
            "orgStudyIdInfo": {
                "id": "GS-US-528-6363"
            },
            "organization": {
                "fullName": "Gilead Sciences",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)",
            "officialTitle": "A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs",
            "acronym": "PURPOSE 4",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "study-of-lenacapavir-and-emtricitabine-tenofovir-disoproxil-fumarate-f-tdf-for-prevention-of-hiv-in-people-who-inject-drugs-hptn"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-10-20",
            "studyFirstSubmitQcDate": "2023-10-20",
            "studyFirstPostDateStruct": {
                "date": "2023-10-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-01",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Gilead Sciences",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "HIV Prevention Trials Network",
                    "class": "NETWORK"
                },
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                },
                {
                    "name": "National Institute of Allergy and Infectious Diseases (NIAID)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goals of this clinical study are to look at how lenacapavir (LEN) passes through the body and to assess the safety of LEN and emtricitabine/tenofovir disoproxil fumarate (F/TDF) for pre-exposure prophylaxis (PrEP) in people who inject drugs (PWID) in the United States (US).\n\nThe primary objectives of this study are to characterize the pharmacokinetics (PK) of LEN and to evaluate the safety of LEN and F/TDF for PrEP in US PWID."
        },
        "conditionsModule": {
            "conditions": [
                "Pre-Exposure Prophylaxis of HIV Infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "PREVENTION",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 250,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Randomized Phase: Lenacapavir (LEN) Group",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive subcutaneous (SC) LEN 927 mg on Day 1 and Week 26 and oral LEN 600 mg on Days 1 and 2.",
                    "interventionNames": [
                        "Drug: Lenacapavir Injection",
                        "Drug: Lenacapavir Tablet"
                    ]
                },
                {
                    "label": "Randomized Phase: Emtricitabine/ Tenofovir Disoproxil Fumarate (F/TDF) Group",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive daily F/TDF (200/300 mg) fixed dose combination (FDC) tablets for up to 52 weeks.",
                    "interventionNames": [
                        "Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)"
                    ]
                },
                {
                    "label": "Pharmacokinetic (PK) Tail Phase: F/TDF",
                    "type": "EXPERIMENTAL",
                    "description": "After the completion of the Randomized Phase, participants in LEN group will be transitioned to receive F/TDF FDC tablets and participants in F/TDF group will continue to receive F/TDF FDC tablets in the PK Tail Phase. All participants will receive F/TDF FDC tablets, once daily for up to 78 weeks beginning 26 weeks after the last LEN injection.",
                    "interventionNames": [
                        "Drug: Emtricitabine/tenofovir disoproxil fumarate (F/TDF)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Lenacapavir Injection",
                    "description": "Administered subcutaneously",
                    "armGroupLabels": [
                        "Randomized Phase: Lenacapavir (LEN) Group"
                    ],
                    "otherNames": [
                        "GS-6207"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Lenacapavir Tablet",
                    "description": "Administered orally",
                    "armGroupLabels": [
                        "Randomized Phase: Lenacapavir (LEN) Group"
                    ],
                    "otherNames": [
                        "GS-6207"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Emtricitabine/tenofovir disoproxil fumarate (F/TDF)",
                    "description": "Administered orally",
                    "armGroupLabels": [
                        "Pharmacokinetic (PK) Tail Phase: F/TDF",
                        "Randomized Phase: Emtricitabine/ Tenofovir Disoproxil Fumarate (F/TDF) Group"
                    ],
                    "otherNames": [
                        "Truvada\u00ae"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Pharmacokinetic (PK) Parameter: Ctrough for Lenacapavir (LEN): LEN Plasma concentration at the End of the Dosing Interval (Week 26)",
                    "timeFrame": "Week 26"
                },
                {
                    "measure": "PK Parameter: Ctrough for LEN: LEN Plasma concentration at the End of the Dosing Interval (Week 52)",
                    "timeFrame": "Week 52"
                },
                {
                    "measure": "Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)",
                    "timeFrame": "First dose date up to 30 days post last dose at Week 78"
                },
                {
                    "measure": "Percentage of Participants Experiencing Treatment-emergent Clinical Laboratory Abnormalities with LEN and F/TDF",
                    "timeFrame": "First dose date up to 30 days post last dose at Week 78"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "General Acceptability of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Acceptability Questionnaire Responses",
                    "description": "To assess the acceptability of the study drug, the participants will complete questionnaire including a question on general acceptability of the assigned study drug on an ordinal 5-category scale with a response of: Completely unacceptable, Unacceptable, No opinion, Acceptable, or Completely acceptable.",
                    "timeFrame": "Up to Week 52"
                },
                {
                    "measure": "Satisfaction With Use of LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Satisfaction Questionnaire Responses",
                    "description": "To assess the satisfaction with use of the study drug, the participants will complete questionnaire including a question on satisfaction with use of the assigned study drug on an ordinal 5-category scale with a response of: Very satisfied, Satisfied, Neutral, Dissatisfied, or Very dissatisfied.",
                    "timeFrame": "Up to Week 52"
                },
                {
                    "measure": "Willingness to Use LEN and F/TDF as PrEP as Assessed by Percentage of Participants with Willingness to Use Questionnaire Responses",
                    "description": "To assess the willingness to use the study drug, the participants will complete questionnaire including a question on willingness to use the assigned study drug on an ordinal 5-category scale with a response of: Definitely Yes, Probably yes, Not sure/undecided, Probably No, or Definitely No.",
                    "timeFrame": "Up to Week 52"
                },
                {
                    "measure": "Number of Participants with Adherence to LEN, as Assessed by On-time LEN Injections Received",
                    "timeFrame": "Up to Week 26"
                },
                {
                    "measure": "Number of Participants with Adherence to F/TDF as Assessed by Adherence Levels Based on Intracellular Tenofovir-diphosphate (TFV-DP) Concentrations in Dried Blood Spot (DBS)",
                    "timeFrame": "Up to Week 78"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Urine drug screen positive for any drug of misuse including, but not limited to, opioids (eg, fentanyl, heroin), stimulants (eg, cocaine, amphetamines), psychoactive drugs (eg, benzodiazepines), or a combination of these drugs.\n* Evidence of recent injection (eg, track marks).\n* Self-report of injection paraphernalia sharing in the prior 30 days.\n* Hepatitis B virus (HBV) surface antigen (HBsAg) negative.\n* Negative local rapid HIV-1/2 antibody (Ab)/antigen (Ag) test, central HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).\n* Estimated glomerular filtration rate (GFR) at least 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).\n\nKey Exclusion Criteria:\n\n* Self-reported history of previous positive results on an HIV test.\n* Any reactive or positive HIV test result at screening or enrollment, even if HIV infection is not confirmed.\n* Coenrollment in any other interventional research study or other concurrent studies that may interfere with this study (as provided by self-report or other available documentation) without prior approval from the Medical Monitor/Joint Clinical Management Committee while participating in this study.\n* Past or current participation in HIV vaccine or HIV broadly neutralizing antibody study unless individual provides documentation of receipt of placebo (ie, not active product).\n* Prior use of long-acting systemic pre-exposure prophylaxis (PrEP) (including cabotegravir (CAB) or islatravir studies).\n* Acute viral hepatitis A or acute or chronic hepatitis B or C infection.\n* Have a suspected or known active, serious infection(s) (eg, active tuberculosis, etc).\n* Evidence of moderate or severe liver fibrosis or a history of or current clinical decompensated liver cirrhosis (eg, ascites, encephalopathy, variceal bleeding)\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Gilead Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-833-445-3230 (GILEAD-0)",
                    "email": "GileadClinicalTrials@gilead.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Gilead Study Director",
                    "affiliation": "Gilead Sciences",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCSD AntiViral Research Center (AVRC)",
                    "status": "RECRUITING",
                    "city": "San Diego",
                    "state": "California",
                    "zip": "92103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.71533,
                        "lon": -117.15726
                    }
                },
                {
                    "facility": "Rutgers New Jersey Medical School, Department of Medicine",
                    "status": "RECRUITING",
                    "city": "Newark",
                    "state": "New Jersey",
                    "zip": "07103",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.73566,
                        "lon": -74.17237
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Gilead Clinical Trials Website",
                    "url": "https://www.gileadclinicaltrials.com/study?nctid=NCT06101342"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015658",
                    "term": "HIV Infections"
                }
            ],
            "ancestors": [
                {
                    "id": "D000086982",
                    "term": "Blood-Borne Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000015229",
                    "term": "Sexually Transmitted Diseases, Viral"
                },
                {
                    "id": "D000012749",
                    "term": "Sexually Transmitted Diseases"
                },
                {
                    "id": "D000016180",
                    "term": "Lentivirus Infections"
                },
                {
                    "id": "D000012192",
                    "term": "Retroviridae Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000007153",
                    "term": "Immunologic Deficiency Syndromes"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3522",
                    "name": "Acquired Immunodeficiency Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M18250",
                    "name": "HIV Infections",
                    "asFound": "HIV Infections",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2593",
                    "name": "Blood-Borne Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15558",
                    "name": "Sexually Transmitted Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17933",
                    "name": "Sexually Transmitted Diseases, Viral",
                    "relevance": "LOW"
                },
                {
                    "id": "M18640",
                    "name": "Lentivirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15026",
                    "name": "Retroviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M10199",
                    "name": "Immunologic Deficiency Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068698",
                    "term": "Tenofovir"
                },
                {
                    "id": "D000068679",
                    "term": "Emtricitabine"
                },
                {
                    "id": "D000069480",
                    "term": "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000998",
                    "term": "Antiviral Agents"
                },
                {
                    "id": "D000000890",
                    "term": "Anti-Infective Agents"
                },
                {
                    "id": "D000018894",
                    "term": "Reverse Transcriptase Inhibitors"
                },
                {
                    "id": "D000019384",
                    "term": "Nucleic Acid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000019380",
                    "term": "Anti-HIV Agents"
                },
                {
                    "id": "D000044966",
                    "term": "Anti-Retroviral Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M296",
                    "name": "Tenofovir",
                    "asFound": "1 month",
                    "relevance": "HIGH"
                },
                {
                    "id": "M294",
                    "name": "Emtricitabine",
                    "asFound": "Birth",
                    "relevance": "HIGH"
                },
                {
                    "id": "M448",
                    "name": "Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination",
                    "asFound": "Respiratory Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4314",
                    "name": "Antiviral Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4214",
                    "name": "Anti-Infective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20935",
                    "name": "Reverse Transcriptase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M21350",
                    "name": "Anti-HIV Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M25428",
                    "name": "Anti-Retroviral Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}